Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

Prurisol had stellar preclinical results. Phase 2a showed a weak signal that suggested they may have under-dosed the trial. A chance was taken on a Phase 2b trial based on the strong preclinical results and the signal in the phase 2a trial.

It wasn't junk science. It was a sound call made with limited data which ended up being wrong in the end. Unfortunately not everything works out the way we want it to in clinical trials.

B-OM results were much better than the Prurisol signal especially when you consider the secondary endpoints (which could make it a billion dollar indication on their own.)